BASF is courting political leaders and its own largest takeover target’s anchor shareholder with a package of plant, job and training pledges — but the gestures sketched so far carry more symbolism than substance, and investors have a bigger question to answer before the November 23 Capital Markets Day: whether any of this capital deployment, takeover or otherwise, can be economically justified.
Shares in the Ludwigshafen-based chemicals group slipped 2.9% on Tuesday as the market weighed the latest maneuvering around Evonik. Reuters reported that BASF outlined possible commitments on sites, employment and apprenticeships in a letter to North Rhine-Westphalia’s state government and to the RAG Foundation, Evonik’s biggest shareholder. Bloomberg, meanwhile, said the company could rule out compulsory redundancies for a period still to be negotiated and keep all German production sites running, alongside spending on research and development and the climate-friendly conversion of its operations. A further improved bid could follow within days, according to that report — though its size remains unknown.
A Draft Full of Blanks
The Handelsblatt, for its part, has seen a draft dated November 11. It would continue existing employee commitments, keep the Marl and Wesseling chemical parks in operation and preserve
That is the crux of the resistance. Back in late October, BASF had already committed to taking on Evonik’s employment guarantees through 2032 and to keeping Marl and Wesseling running with roughly 3,500 jobs. Repeating known pledges, Evonik works council representative Hussin El Moussaoui argued, creates no added value. The Reuters-sourced draft still contains placeholders for time frames and investment sums, leaving the key economic terms unresolved.
Evonik has already turned down an improved offer worth more than EUR 11 billion, or EUR 24 per share. Any fresh approach would therefore not be BASF’s first attempt to win the company’s consent — and securing the RAG Foundation’s backing would carry particular weight given its status as the largest Evonik shareholder. BASF is also lobbying lawmakers for support. Neither company would comment to Dow Jones.
Should investors sell immediately? Or is it worth buying BASF?
The Cost of Promises
For BASF, the tension is straightforward. Deeper commitments might smooth the path to a deal, but job and site guarantees can also curb savings from headcount cuts or consolidation — which in turn caps the price that makes economic sense. A new offer price on its own would tell only part of the story; investors also need the duration of any guarantees and binding investment totals. Until those are settled, the financial reach of the planned concessions cannot be fully assessed.
The Evonik question, though, is only one strand of a broader capital allocation story. On November 11, BASF commissioned a new MDI production plant at its Geismar Verbund site, a roughly USD 1 billion investment that lifts annual MDI capacity there to around 600,000 metric tons. The facility is already running, which gives the debate a concrete reference point — but added capacity alone does not answer how much it will contribute to earnings. What matters is how existing investments and potential new obligations fit together.
Soy, Spreads and a Skeptical Analyst
BASF is not relying on acquisitions alone to broaden its growth path. On Monday it announced plans to launch soybean varieties carrying the Nemasphere trait in the US and Brazil from 2028, with peak sales potential put at more than EUR 300 million. That figure is an expectation, not revenue already booked. Alongside the Geismar start-up, it points to an investment picture that does not hinge solely on buying assets. The agreed sale of the global Mining Solutions business to SNF belongs in the same frame: BASF is shedding activities even as it invests and pursues Evonik. That transaction is due to close in 2027, subject to regulatory approvals and customary conditions, with no financial details disclosed.
The counterargument is rooted in the trading environment. Jefferies downgraded BASF from “Hold” to “Underperform” last Wednesday, setting a EUR 44 price target and citing persistently weak chemical spreads and overcapacity. More capacity and fresh commitments would be harder to justify if margins stay compressed. Additional concessions in the Evonik effort would first address political and social support; whether they translate into an economically convincing transaction is a separate judgment. Planned divestments, likewise, are not completed deals.
When BASF lays out its priorities on November 23, the test will not be the sheer number of projects on the table. It will be whether the mix of site expansion, product development and portfolio change adds up to a coherent relationship between opportunity, capital employed and risk.
Ad
BASF Stock: Buy or Sell?! New BASF Analysis from November 18 delivers the answer:
The latest BASF figures speak for themselves: Urgent action needed for BASF investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 18.
BASF: Buy or sell? Read more here...
